A Two Year Study of the Clinical Efficacy of the Combination of Emtricitabine, Tenofovir, and Nevirapine

Phase 4 Completed 54 enrolled University of Maryland, Baltimore Boehringer Ingelheim · collab

NaSingle-groupOpen-labelTreatment

Summary

Open label, two year study of the clinical efficacy of the combination of FTC, Tenofovir, and Nevirapine. Sixty HIV infected patients without previous exposure to antiretroviral therapy will be enrolled. Study will include a pharmacokinetic substudy to evaluate the interaction of FTC and Nevirapine. Truvada may be used.

Timeline

Start: 2004-03
Primary completion: 2008-07
Completion: 2008-07

Publications

Amoroso A, Gilliam BL, Talwani R, Boyce C, Redfield RR, Davis CE. Viral load decay in antiretroviral-naive patients receiving once-daily tenofovir and emtricitabine plus twice-daily nevirapine. HIV Clin Trials. 2009 Sep-Oct;10(5):320-3. doi: 10.1310/hct1005-320.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nevirapine	Small molecule	200 mg	—
Subject	Tenofovir	Small molecule	300 mg	Oral
Subject	emtricitabine	Other / unclassified	200 mg	Oral

A Two Year Study of the Clinical Efficacy of the Combination of Emtricitabine, Tenofovir, and Nevirapine

Summary

Timeline

Publications

Drugs

Indications